Vitrafy Posts 75% Sales Growth and $29.6M Cash Ahead of Product Launches

Strong FY25 Performance and Market Momentum

Vitrafy Life Sciences Limited (ASX, VFY) has delivered on its IPO commitments with a notable 75% increase in sales revenue for FY25, propelled by growth in aquaculture and its partnership with Huon. The company’s cash and liquid assets stand at a healthy $29.6 million, providing a runway through to calendar year 2027 despite elevated expenditure planned for FY26.

Operationally, Vitrafy has made significant strides in advancing its next-generation cryopreservation technology. The detailed design of its VCU2 hardware is well advanced, with the build phase now underway. Complementing this, the LifeChain software upgrade is progressing on schedule, aiming to enhance functionality and integration critical for commercial deployment.

Breakthroughs in Blood Platelet and Animal Reproduction Markets

Vitrafy’s Phase 1 blood platelet study, conducted in collaboration with the U.S. Military, has yielded outstanding results, surpassing current industry standards. This milestone has paved the way for a Phase 2 study scheduled to commence in the first quarter of FY26, bringing the company closer to commercialisation in this high-value segment.

In parallel, Vitrafy has expanded its footprint in animal reproduction and aquaculture markets. Commercial activities have grown with existing and new partners, supported by data validating the competitive advantage of Vitrafy’s cryopreservation technology. Trials with Select Sires, Inc. and other collaborators continue to explore global market opportunities, particularly in bovine applications.

Financial Highlights and Capital Structure

While FY25 results were impacted by one-off non-cash costs related to convertible note conversions and share-based payments aligned with a new executive incentive plan, the company’s normalised loss before tax stood at $11.3 million. Vitrafy also secured a $4.8 million commercialisation grant from the Australian Industry Growth Fund, supporting ongoing innovation and growth initiatives.

The balance sheet remains robust, with $10.1 million held in term deposits and deferred income reflecting grant receipts matched to expenditure. The company’s financial position supports its aggressive plans to scale U.S. operations and expand commercial collaborations.

Clear Commercialisation Roadmap for FY26

Looking ahead, Vitrafy is focused on revenue-generating activities with a clear timeline for product launches. The company plans to release its unregulated cryopreservation product in the first half of FY26, followed by a regulated medical device launch in the U.S. market in the second half. Building supply chain and manufacturing capabilities is also a priority to support scale.

With a strengthened leadership team transition imminent, Brent Owens, co-founder and technology pioneer, will assume CEO duties from September 1, 2025, Vitrafy is positioning itself to capture global commercial opportunities across human health and animal reproduction sectors.